As the commercial industry grows and CBD becomes acknowledged and accepted as a benefit in large scale, it puts CBD under a microscope. In some ways that is a huge risk to the industry but on the contrary could be the path to help it completely take off.
CVS is on the top 10 companies on Fortune 500 with a $180 billion annual revenue. They stand out in being a company promoting health. For instance, they were the first drug store to stop selling tobacco products. CVS is being cautious in incorporating the sales of CBD products by starting sales in a small percentage of their over 10,000 locations in the US. Being a health first company, we know that the risk of taking on CBD products will only raise their reputation. To start, only eight states will begin carrying these CBD products; Illinois, Colorado, Alabama, California, Kentucky, Tennessee, Maryland, and Indiana. There will be no sales of edibles or CBD-derived supplements. The products available for purchase are topicals including lotions, roll-ons, sprays, salves, and creams in reducing pain and inflamation with. With brands such as Elevate CBD, Medterra, and Curaleaf producing cooling/warming creams, patches, and sprays, some with 140mg of cannabinoids and importantly less than 0.3% THC.
Walgreens has also stated their intention to sell CBD products along with major companies such as DSW, Free People, Authentic Brands Group, Neiman Marcus, and Sephora who are involved in CBD. It is positive news that CBD is going mainstream and since the 2018 Farm Bill, it is now easier than ever to attain premium grade cannabidiol. The CBD Market is said to be worth 22 billion within 3 years. As the industry grows, mainstream sales should only increase the value and reputation of CBD.